Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato Sells 1,020 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 1,020 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the completion of the sale, the director now owns 111,056 shares in the company, valued at approximately $3,331,680. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Denali Therapeutics Stock Down 5.4 %

NASDAQ:DNLI opened at $29.89 on Wednesday. The stock’s 50-day simple moving average is $28.05 and its 200 day simple moving average is $23.84. The firm has a market capitalization of $4.30 billion, a PE ratio of -10.83 and a beta of 1.40. Denali Therapeutics Inc. has a twelve month low of $14.56 and a twelve month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the business earned ($0.72) earnings per share. On average, analysts anticipate that Denali Therapeutics Inc. will post -2.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DNLI. Citigroup increased their price target on Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. decreased their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Cantor Fitzgerald lowered Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Jefferies Financial Group upped their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Bank of America upped their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $38.90.

Institutional Trading of Denali Therapeutics

Several large investors have recently bought and sold shares of DNLI. GAMMA Investing LLC raised its position in Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock valued at $48,000 after purchasing an additional 1,847 shares during the last quarter. CWM LLC raised its position in Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after purchasing an additional 654 shares during the last quarter. Quest Partners LLC bought a new position in Denali Therapeutics in the third quarter valued at about $73,000. Headlands Technologies LLC bought a new position in Denali Therapeutics in the first quarter valued at about $88,000. Finally, Assetmark Inc. raised its position in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.